Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Guideline
. 2005 May 9;92(9):1599-610.
doi: 10.1038/sj.bjc.6602550.

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

M O Leach  1 , K M Brindle, J L Evelhoch, J R Griffiths, M R Horsman, A Jackson, G C Jayson, I R Judson, M V Knopp, R J Maxwell, D McIntyre, A R Padhani, P Price, R Rathbone, G J Rustin, P S Tofts, G M Tozer, W Vennart, J C Waterton, S R Williams, P Workman; Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK
Affiliations
Guideline

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

M O Leach et al. Br J Cancer. .

Abstract

Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Example of Ktrans maps, superimposed on T1-weighted images of a patient with primary peritoneal carcinoma with left pelvic side wall nodal metastases (arrow). Images are before and 4 h after the first dose of Combretastatin (52 mg m−2). The colour scale ranges from Ktrans values of 0 to 1 min−1. A dramatic reduction of transfer constant is seen. This was published with kind permission from the Journal of Magnetic Resonance Imaging (Padhani, 2002).
See this image and copyright information in PMC

References

    1. Alessi P, Ebbinghaus C, Neri D (2004) Molecular targeting of angiogenesis. Biochim Biophys Acta 1654: 39–49 - PubMed
    1. Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR, Cosgrove GR, Halpern EF, Hochberg FH (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191: 41–51 - PubMed
    1. Barbier EL, den Boer JA, Peters AR, Rozeboom AR, Sau J, Bonmartin A (1999) A model of the dual effect of gadopentetate dimeglumine on dynamic brain MR images. J Magn Reson Imaging 10: 242–253 - PubMed
    1. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, Solaiyappan M (2001) Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 3: 143–153 - PMC - PubMed
    1. Bicknell R, Harris AL (1996) Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol 8: 60–65 - PubMed

Publication types

MeSH terms

Substances